Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery
Status:
Completed
Trial end date:
2001-06-01
Target enrollment:
Participant gender:
Summary
We conducted a multicenter, randomized, placebo-controlled trial of Cylexin, an inhibitor of
the attachment of white blood cells to the endothelium. Our study population was neonates and
infants undergoing hypothermic cardiopulmonary bypass during surgical repair or palliation of
congenital heart defects.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital